Melanoma Sensitivity

Despite remarkable efforts, metastatic melanoma still presents with significant mortality.

Funding Period:

01.08.2015 - 28.02.2018

Project description:

By combining statistical and network modeling and systems analysis with basic research and clinical data we aim to elucidate mechanisms of therapy-resistance of melanoma and to identify combinatorial systems biomarkers to prognosticate treatment responsiveness of BRAF mutated metastatic melanoma to BRAF (dabrafenib) / MEK (trametenib) inhibitors and to TRAIL death receptor agonists.

Project coordination

This image shows Roland Kontermann
Prof. Dr.

Roland Kontermann

Deputy Head of the Institute (Biomedical Engineering)

To the top of the page